Which Healthcare ETF Is the Better Buy: Invesco's IBBQ or State Street's XPH?

The Invesco Nasdaq Biotechnology ETF is positioned as the lower-cost option with a lower expense ratio and a higher trailing dividend yield versus the State Street SPDR S&P Pharmaceuticals ETF. The change is primarily product/fee related rather than a broad fundamental re-rating. Overall, the update is mildly positive for income-focused investors comparing ETF structures.

Analysis

The Invesco Nasdaq Biotechnology ETF is positioned as the lower-cost option with a lower expense ratio and a higher trailing dividend yield versus the State Street SPDR S&P Pharmaceuticals ETF. The change is primarily product/fee related rather than a broad fundamental re-rating. Overall, the update is mildly positive for income-focused investors comparing ETF structures.